An international clinical trial has achieved a new effective treatment option for rare epilepsy that can reduce seizures by 91% in children. Here is what this breakthrough means for the children ...

A first-in-class gene-regulating therapy cut seizures by up to 91% in children with Dravet syndrome in extension studies, ...

A new experimental drug is showing remarkable promise for children with Dravet syndrome, a severe genetic form of epilepsy.

Xenon Pharmaceuticals Inc. XENE-Q generated positive results from a critical late-stage human trial for its epilepsy ...

A pioneering gene therapy could help treat a rare seizure disorder called Dravet syndrome, according to new clinical trial ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more ...

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg ...

An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.

Dr Pavel Klein discusses strategies to address patient skepticism and improve seizure reporting to enhance clinical outcomes in epilepsy.

Magnetic seizure therapy (MST) offers similar efficacy as electroconvulsive therapy (ECT) in treating bipolar mania in adults, with significantly fewer adverse effects on language abilities, new ...

Epileptic seizures alter sleep by prolonging the stage that's central to memory formation, potentially predisposing the brain ...

A new form of gene therapy designed to treat the most treatment-resistant form of childhood epilepsy appears to reduce seizures in mice. In a research article published Dec. 14 in Brain, researchers ...